| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| rilotumumab | hepatocyte growth factor | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Glioma[MeSHID:D005910] |
13.26 | discontinued in phase 2 | antibody |
| rilotumumab | hepatocyte growth factor | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Glioma[MeSHID:D005910] |
13.26 | discontinued in phase 2 | inhibitor |
| click here to return to the previous page | ||||||||